Toxicity of serotonin-norepinephrine reuptake inhibitors (SNRIs) during pregnancy and lactation

Abstract

Major depressive disorder (depression) is a severe mood disorder. Lifestyle changes during the COVID-19 pandemic contributed to the high incidence of depression in the population. The primary care treatment is provided by both psychotherapy and antidepressants. In the last 35years,selective serotoninreuptakeinhibitors (SSRIs)were used because of lower adverse effects when compared to tricyclic antidepressants and monoamine oxidase (MAO) inhibitors. However, selective serotonin–norepinephrine reuptake inhibitors (SNRIs), which are second-generation antidepressants, are preferred over first-generation antidepressants by some physicians as they have broad uses nowadays. Anxiety disorders, depression, social phobia, attention-deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), fibromyalgia syndrome, chronic neuropathic pain, and menopausal symptoms are among the conditions that can be treated with SNRIs. Although the effects of genetic factors and family history on these diseases, especially recurrence, are undeniable, these drugs provide a great deal of improvement. However, the use of SNRIs during pregnancy and lactation is still a debate. There is no definite judgment on whether a pregnant woman should use these drugs during pregnancy or not. As the rate of depression among pregnant women increases, this issue becomes more serious. A definitive answer has not been reached yet because studies on pregnant women cannot be carried out within the framework of ethical rules. In this review, the effects, toxicity, and safety of SNRIs during pregnancy and lactation are discussed.

Keywords

• SNRI
• antidepressant
• serotonin
• norepinephrine
• pregnancy
• lactation

References

1. Ankarfeldt, M. Z., Petersen, J., Andersen, J. T., Li, H., Mot-sko, S. P., Fast, T.... Jimenez-Solem, E. (2021). Expo-sure to duloxetine during pregnancy and risk of congeni-tal malformations and stillbirth: A nationwide cohort study in Denmark and Sweden. Plos Medicine, 18(11), e1003851. https://doi.org/10.1371/journal.pmed.1003851 google scholar
2. American Psychiatric Association (2023, September). Di-agnostic and Statistical Manual of Mental Disor-ders (DSM-5-TR) [Web log post]. Retrieved from: https://www.psychiatry.org/psychiatrists/practice/dsm/updates-to-dsm/updates-to-dsm-5-tr-criteria-text google scholar
3. Armstrong, C. (2008). ACOG guidelines on psychiatric medication use during pregnancy and lactation. American Family Physician, 78(6), 772-778. google scholar
4. Auclair, A. L., Martel, J. C., Assie, M. B., Bardin, L., Heusler, P., Cussac, D. ... Depoortere, R. (2013). Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in mod-els of depression and anxiety. Neuropharmacology, 70, 338-347. https://doi.org/10.1016/j.neuropharm.2013.02.024 google scholar
5. Avalos, L. A., Chen, H., & Li, D. K. (2015). Antidepressant medication use, depression, and the risk of preeclampsia. CNS Spectrums, 20(1), 39-47. https://doi.org/10.1017/S1092852915000024 google scholar
6. Banzi, R., Cusi, C., Randazzo, C., Sterzi, R., Tedesco, D., & Moja, L. (2015). Selective serotonin reuptake in-hibitors (SSRIs) and serotonin-norepinephrine reuptake in-hibitors (SNRIs) for the prevention of migraine in adults. The Cochrane Database Of Systematic Reviews, 4(4), CD002919. https://doi.org/10.1002/14651858.CD002919.pub3 google scholar
7. Bellantuono, C., Marini, A., & Lucarelli, C. (2013). Infant health and neurodevelopmental outcomes following prenatal exposure to duloxetine. Clinical Drug Investigation, 33(9), 685 688. https://doi.org/10.1007/s40261-013-0112-y google scholar
8. Bellantuono, C., Vargas, M., Mandarelli, G., Nardi, B., & Martini, M. G. (2015). The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a compre-hensive review. Human Psychopharmacology, 30(3), 143-151. https://doi.org/10.1002/hup.2473 google scholar

9. Bellingham, G. A., & Peng, P. W. (2010). Duloxetine: a re-view of its pharmacology and use in chronic pain manage-ment. Regional Anesthesia And Pain Medicine, 35(3), 294-303. https://doi.org/10.1097/AAP.0b013e3181df2645 google scholar
10. Benevent, J., Araujo, M., Karki, S., Delarue-Hurault, C., Waser, J., Lacroix, I.... Damase-Michel, C. (2023). Risk of Hyperten- google scholar
11. sive Disorders of Pregnancy in Women Treated With Serotonin-Norepinephrine Reuptake Inhibitors: A Comparative Study Using the EFEMERIS Database. The Journal Of Clinical Psychiatry, 84(4), 22m14734. https://doi.org/10.4088/JCP.22m14734 google scholar
12. Berard, A., Zhao, J. P., & Sheehy, O. (2017). Antidepressant use dur-ing pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open, 7(1), e013372. https://doi.org/10.1136/bmjopen-2016-013372 google scholar
13. Boucher, N., Koren, G., & Beaulac-Baillargeon, L. (2009). Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations. Therapeutic Drug Monitoring, 31(3), 404-409. https://doi.org/10.1097/FTD.0b013e3181a58fb4 google scholar
14. Boyce, P. M., Hackett, L. P., & Ilett, K. F. (2011). Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Archives Of Women’s Mental Health, 14(2), 169-172. https://doi.org/10.1007/s00737-011-0215-5 google scholar
15. Briggs, G. G., Ambrose, P. J., Ilett, K. F., Hackett, L. P., Nageotte, M. P., & Padilla, G. (2009). Use of duloxetine in pregnancy and lactation. The Annals Of Pharmacotherapy, 43(11), 1898-1902. https://doi.org/10.1345/aph.1M317 google scholar
16. Brumbaugh, J. E., Ball, C. T., Crook, J. E., Stoppel, C. J., Carey, W. A., & Bobo, W. V. (2023). Poor Neonatal Adaptation After Antidepressant Exposure During the Third Trimester in a Geographically Defined Cohort. Mayo Clinic Proceedings. Innovations, Quality & Outcomes, 7(2), 127-139. https://doi.org/10.1016/j.mayocpiqo.2023.02.002 google scholar
17. Bruno, A., Morabito, P., Spina, E., & Muscatello, M. R. (2016). The Role of Levomilnacipran in the Man-agement of Major Depressive Disorder: A Comprehen-sive Review. Current Neuropharmacology, 14(2), 191-199. https://doi.org/10.2174/1570159x14666151117122458 google scholar
18. Cowen, P. J., Ogilvie, A. D., & Gama, J. (2005). Efficacy, safety, and tolerability of duloxetine 60 mg once daily in major depres-sion. Current Medical Research And Opinion, 21(3), 345-356. https://doi.org/10.1185/030079905X30680 google scholar
19. Dale, E., Bang-Andersen, B., & Sanchez, C. (2015). Emerg-ing mechanisms and treatments for depression beyond SS-RIs and SNRIs. Biochemical Pharmacology, 95(2), 81-97. https://doi.org/10.1016/j.bcp.2015.03.011 google scholar
20. Dandjinou, M., Sheehy, O., & Berard, A. (2019). Antidepressant use during pregnancy and the risk of gestational diabetes mel-litus: a nested case-control study. BMJ Open, 9(9), e025908. https://doi.org/10.1136/bmjopen-2018-025908 google scholar
21. Deecher, D. C., Beyer, C. E., Johnston, G., Bray, J., Shah, S., Abou-Gharbia, M., & Andree, T. H. (2006). Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. The Jour-nal Of Pharmacology And Experimental Therapeutics, 318(2), 657-665. https://doi.org/10.1124/jpet.106.103382 google scholar
22. DeMaio, W., Kane, C., Nichols, A., & Jordan, R. (2011). Metabolism studies of desvenlafaxine. Journal Of Bioequivalence & Bioavail-ability, 3(7), 151-160. https://doi.org/10.4172/jbb.1000076 google scholar
23. Dubovicky, M., Belovicova, K., Csatlosova, K., & Bogi, E. (2017). Risks of using SSRI / SNRI antidepressants during preg-nancy and lactation. Interdisciplinary Toxicology, 10(1), 30-34. https://doi.org/10.1515/intox-2017-0004 google scholar
24. Einarson, A., Smart, K., Vial, T., Diav-Citrin, O., Yates, L., Stephens, S.... Einarson, T. R. (2012). Rates of major malformations in infants following exposure to duloxetine during pregnancy: a pre-liminary report. The Journal of Clinical Psychiatry, 73(11), 1471. https://doi.org/10.4088/JCP.12l08013 google scholar
25. Eyal, R., & Yaeger, D. (2008). Poor neonatal adaptation after in utero exposure to duloxetine. The American Journal Of Psychiatry, 165(5), 651. https://doi.org/10.1176/appi.ajp.2008.07071194 google scholar
26. Fanelli, D., Weller, G., & Liu, H. (2021). New Serotonin-Norepinephrine Reuptake Inhibitors and Their Anesthetic and Analgesic Considerations. Neurology International, 13(4), 497-509. https://doi.org/10.3390/neurolint13040049 google scholar
27. Fasipe, O. J. (2018). Neuropharmacological classification of an-tidepressant agents based on their mechanisms of action. Archives Of Medicine And Health Sciences, 6(1), 81-94. https://doi.org/10.4103/amhs.amhs_7_18 google scholar
28. FDA Approved Drug Products. (2011). PRISTIQ® (desven-lafaxine) Extended-Release Tablets. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/0219 92s030lbl.pdf google scholar
29. FDA Center for Drug Evaluation and Research. (2012). F2695 (Levomilnacipran HCl). Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/20416 8Orig1s000PharmR.pdf google scholar
30. FDA Approved Drug Products. (2017). EFFEXOR XR® (ven-lafaxine Extended-Release) Capsules. Retrieved from : https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/0206 99s107lbl.pdf google scholar
31. Fogelman, S. M., Schmider, J., Venkatakrishnan, K., von Moltke, L. L., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (1999). O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology: Official Publication Of The Amer-ican College Of Neuropsychopharmacology, 20(5), 480-490. https://doi.org/10.1016/S0893-133X(98)00113-4 google scholar
32. Frampton, J. E., Plosker, G. L. (2007). Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs, 21(7), 581-609. https://doi.org/10.2165/00023210-200721070-00004 google scholar
33. Galecki, P., Mossakowska-Wojcik, J., & Talarowska, M. (2018). The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs. Progress In Neuro-Psychopharmacology & Biological Psychiatry, 80(Pt C), 291-294. https://doi.org/10.1016/j.pnpbp.2017.03.016 google scholar
34. Ghimire, U., Papabathini, S. S., Kawuki, J., Obore, N., & Musa, T. H. (2021). Depression during pregnancy and the risk of low birth weight, preterm birth and intrauterine growth restriction- an up-dated meta-analysis. Early Human Development, 152, 105243. https://doi.org/10.1016/j.earlhumdev.2020.105243 google scholar
35. Gupta, S., Nihalani, N., & Masand, P. (2007). Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychi-atric disorders. Annals Of Clinical Psychiatry : Official Journal Of The American Academy Of Clinical Psychiatrists, 19(2), 125-132. https://doi.org/10.1080/10401230701333319 google scholar
36. Hoog, S. L., Cheng, Y., Elpers, J., & Dowsett, S. A. (2013). Du-loxetine and pregnancy outcomes: safety surveillance findings. International Journal Of Medical Sciences, 10(4), 413-419. https://doi.org/10.7150/ijms.5213 google scholar
37. Ilett, K. F., Watt, F., Hackett, L. P., Kohan, R., & Teoh, S. (2010). Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. Therapeutic Drug Monitoring, 32(6), 704-707. https://doi.org/10.1097/FTD.0b013e3181f88f70 google scholar
38. Knadler, M. P., Lobo, E., Chappell, J., & Bergstrom, R. (2011). Duloxetine: clinical pharmacokinetics and drug interactions. Clinical Pharmacokinetics, 50(5), 281-294. https://doi.org/10.2165/11539240-000000000-00000 google scholar
39. Koren, G., Moretti, M., & Kapur, B. (2006). Can venlafaxine in breast milk attenuate the norepinephrine and serotonin reuptake neonatal withdrawal syndrome. Journal Of Obstetrics And Gynaecology Canada : JOGC = Journal D’obstetrique Et Gynecologie Du Canada : JOGC, 28(4), 299-301. https://doi.org/10.1016/S1701-2163(16)32135-1 google scholar
40. Lambert, O., & Bourin, M. (2002). SNRIs: mechanism of action and clinical features. Expert Review Of Neurotherapeutics, 2(6), 849-858. https://doi.org/10.1586/14737175.2.6.849 google scholar
41. Lantz, R. J., Gillespie, T. A., Rash, T. J., Kuo, F., Skinner, M., Kuan, H. Y., & Knadler, M. P. (2003). Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metabolism And Disposition: The Biological Fate Of Chemicals, 31(9), 1142-1150. https://doi.org/10.1124/dmd.31.9.1142 google scholar
42. Larsen, E. R., Damkier, P., Pedersen, L. H., Fenger-Gron, J., Mikkelsen, R. L., Nielsen, R. E., ... Danish Society of Clinical Pharmacology (2015). Use of psychotropic drugs during preg-nancy and breast-feeding. Acta Psychiatrica Scandinavica. Sup-plementum, (445), 1-28. https://doi.org/10.1111/acps.12479 google scholar
43. Lee, Y. C., & Chen, P. P. (2010). A review of SSRIs and SNRIs in neuropathic pain. Expert Opinion On Pharmacotherapy, 11(17), 2813-2825. https://doi.org/10.1517/14656566.2010.507192 google scholar
44. Li, J., Lu, C., Gao, Z., Feng, Y., Luo, H., Lu, T.... Luo, Y. (2020). SNRIs achieve faster antidepressant effects than SSRIs by elevating the concentrations of dopamine in the forebrain. Neuropharmacology, 177, 108237. https://doi.org/10.1016/j.neuropharm.2020.108237 google scholar
45. Liebowitz, M. R., Manley, A. L., Padmanabhan, S. K., Gan-guly, R., Tummala, R., Tourian, K. A. (2008). Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Current Medical Research And Opinion, 24(7), 1877-1890. https://doi.org/10.1185/03007990802161923 google scholar
46. Liebowitz, M. R., & Tourian, K. A. (2010). Efficacy, safety, and tol-erability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials. Primary Care Companion To The Journal Of Clinical Psychiatry, 12(3), PCC.09r00845. https://doi.org/10.4088/PCC.09r00845blu google scholar
47. Lind, J. N., Tinker, S. C., Broussard, C. S., Reefhuis, J., Carmichael, S. L., Honein, M. A., ... National Birth Defects Prevention Study (2013). Maternal medication and herbal use and risk for hypospa-dias: data from the National Birth Defects Prevention Study, 19972007. Pharmacoepidemiology And Drug Safety, 22(7), 783-793. https://doi.org/10.1002/pds.3448 google scholar
48. Maciaszek, J., Pawlowski, T., Hadrys, T., Machowska, M., Wiela-Hojenska, A., & Misiak, B. (2023). The Impact of the CYP2D6 and CYP1A2 Gene Polymorphisms on Re-sponse to Duloxetine in Patients with Major Depression. In-ternational Journal Of Molecular Sciences, 24(17), 13459. https://doi.org/10.3390/ijms241713459 google scholar
49. Magalhâes, P., Alves, G., LLerena, A., & Falcao, A. (2015). Clinical drug-drug interactions: focus on venlafax-ine. Drug Metabolism And Personalized Therapy, 30(1), 3-17. https://doi.org/10.1515/dmdi-2014-0011 google scholar
50. Masarwa, R., Bar-Oz, B., Gorelik, E., Reif, S., Perlman, A., & Matok, I. (2019). Prenatal exposure to selective serotonin reuptake in-hibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a system-atic review, meta-analysis, and network meta-analysis. American Journal Of Obstetrics And Gynecology, 220(1), 57.e1-57.e13. https://doi.org/10.1016/j.ajog.2018.08.030 google scholar
51. Millan M. J. (2002). Descending control of pain. Progress In Neurobiology, 66(6), 355-474. https://doi.org/10.1016/s0301-0082(02)00009-6 google scholar
52. Molenaar, N. M., Bais, B., Lambregtse-van den Berg, M. P., Mul-der, C. L., Howell, E. A., Fox, N. S.... Kamperman, A. M.(2020). The international prevalence of antidepressant uses be-fore, during, and after pregnancy: A systematic review and meta-analysis of timing, type of prescriptions and geograph-ical variability. Journal Of Affective Disorders, 264, 82-89. https://doi.org/10.1016/j.jad.2019.12.014 google scholar
53. Montgomery, S. A., Mansuy, L., Ruth, A., Bose, A., Li, H., & Li, D. (2013). Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. The Journal Of Clinical Psychiatry, 74(4), 363-369. https://doi.org/10.4088/JCP.12m08141 google scholar
54. Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M.... Schatzberg, A. F. (2016). Major depres-sive disorder. Nature Reviews. Disease Primers, 2, 16065. https://doi.org/10.1038/nrdp.2016.65 google scholar
55. Pae C. U. (2011). Desvenlafaxine in the treatment of major de-pressive disorder. Expert Opinion On Pharmacotherapy, 12(18), 2923-2928. https://doi.org/10.1517/14656566.2011.636033 google scholar
56. Park, K., Kim, S., Ko, Y. J., & Park, B. J. (2021). Comparison of risk of cardiovascular disease related adverse events between selective serotonin reuptake inhibitor users and serotonin norepinephrine reuptake inhibitor users in Korean adult patients with depression: retrospective cohort study. Psychiatry Research, 298, 113744. https://doi.org/10.1016/j.psychres.2021.113744 google scholar
57. Perrotta, C., Giordano, F., Colombo, A., Carnovale, C., Castiglioni, M., Di Bernardo, I. ... Vigano, C. (2019). Postpartum Bleeding in Pregnant Women Receiving SSRIs/SNRIs: New Insights From a Descriptive Observational Study and an Analysis of Data from the FAERS Database. Clinical Therapeutics, 41(9), 1755-1766. https://doi.org/10.1016/j.clinthera.2019.06.008 google scholar
58. Preskorn, S., Patroneva, A., Silman, H., Jiang, Q., Isler, J. A., Bur-czynski, M. E.... Nichols, A. I. (2009). Comparison of the pharmacokinetics of venlafaxine extended release and desven-lafaxine in extensive and poor cytochrome P450 2D6 metabo-lizers. Journal Of Clinical Psychopharmacology, 29(1), 39-43. https://doi.org/10.1097/JCP.0b013e318192e4c1 google scholar
59. Rampono, J., Teoh, S., Hackett, L. P., Kohan, R., & Ilett, K. F. (2011). Estimation of desvenlafaxine transfer into milk and in-fant exposure during its use in lactating women with postnatal depression. Archives Of Women’s Mental Health, 14(1), 49-53. https://doi.org/10.1007/s00737-010-0188-9 google scholar
60. Ray, S., & Stowe, Z. N. (2014). The use of antide-pressant medication in pregnancy. Best Practice & Re-search. Clinical Obstetrics & Gynecology, 28(1), 71-83. https://doi.org/10.1016/j.bpobgyn.2013.09.005 google scholar
61. Reddy, S., Kane, C., Pitrosky, B., Musgnung, J., Ninan, P. T., & Guico-Pabia, C. J. (2010). Clinical utility of desven-lafaxine 50 mg/d for treating MDD: a review of two ran-domized placebo-controlled trials for the practicing physi-cian. Current Medical Research And Opinion, 26(1), 139-150. https://doi.org/10.1185/03007990903408678 google scholar
62. Robiyanto, R., Roos, M., Bos, J. H. J., Hak, E., van Puijenbroek, E. P., & Schuiling-Veninga, C. C. M. (2023). Switching pat-tern and dose adjustment of antidepressants before and during pregnancy. Archives Of Women’s Mental Health, 26(5), 685-696. https://doi.org/10.1007/s00737-023-01355-8 google scholar
63. Sansone, R. A., & Sansone, L. A. (2014). Serotonin nore-pinephrine reuptake inhibitors: a pharmacological compari-son. Innovations In Clinical Neuroscience, 11(3-4), 37-42. https://www.ncbi.nlm.nih.gov/pubmed/24800132 google scholar
64. Seo, H. J., Sohi, M. S., Patkar, A. A., Masand, P. S., & Pae, C. U. (2010). Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. Postgraduate Medicine, 122(1), 125-138. https://doi.org/10.3810/pgm.2010.01.2106 google scholar
65. Singal, D., Chateau, D., Struck, S., Lee, J. B., Dahl, M., Derksen, S. ... Brownell, M. (2020). In Utero Antidepressants and Neurode-velopmental Outcomes in Kindergarteners. Pediatrics, 145(5), e20191157. https://doi.org/10.1542/peds.2019-1157 google scholar
66. Snamina, M., Wietecha-Posluszny, R., & Zawadzki, M. (2019). Post-mortem analysis of human bone marrow aspirate - Quantitative determination of SSRI and SNRI drugs. Talanta, 204, 607-612. https://doi.org/10.1016/j.talanta.2019.06.054 google scholar
67. Speroff, L., Gass, M., Constantine, G., Olivier, S., & Study 315 Inves-tigators (2008). Efficacy and tolerability of desvenlafaxine succi-nate treatment for menopausal vasomotor symptoms: a random-ized controlled trial. Obstetrics And Gynecology, 111(1), 77-87. https://doi.org/10.1097/01.AOG.0000297371.89129.b3 google scholar
68. Stahl, S. M., Entsuah, R., & Rudolph, R. L. (2002). Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of pa-tients with depression. Biological Psychiatry, 52(12), 1166-1174. https://doi.org/10.1016/s0006-3223(02)01425-7 google scholar
69. Uguz F. (2018). Maternal Antidepressant Use During Pregnancy and the Risk of Attention-Deficit/Hyperactivity Disorder in Children: A Systematic Review of the Current Literature. Journal Of Clinical Psychopharmacology, 38(3), 254-259. https://doi.org/10.1097/JCP.0000000000000868 google scholar
70. Wang, X. Y., Ying, X. H., & Jiang, H. Y. (2023). Antidepres-sant use during pregnancy and the risk for gestational dia-betes: a systematic review and meta-analysis. The Journal of Maternal-Fetal & Neonatal Medicine: The Official Journal Of The European Association Of Perinatal Medicine, The Fed-eration Of Asia And Oceania Perinatal Societies, The Inter-national Society Of Perinatal Obstetricians, 36(1), 2162817. https://doi.org/10.1080/14767058.2022.2162817 google scholar
71. Wong, D. T., Bymaster, F. P., Mayle, D. A., Reid, L. R., Krushinski, J. H., & Robertson, D. W. (1993). LY248686, a new inhibitor of sero-tonin and norepinephrine uptake. Neuropsychopharmacology: Of-ficial Publication Of The American College Of Neuropsychophar-macology, 8(1), 23-33. https://doi.org/10.1038/npp.1993.4 google scholar
72. Yang, L., Wu, Z., Cao, L., Wang, Y., Su, Y., Huang, J.... Fang, Y. (2021). Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report. Journal Of Psychiatric Research, 138, 96-102. https://doi.org/10.1016/j.jpsychires.2021.03.063 google scholar
73. Yue, M., Kus, L., Katta, S., Su, I., Li, L., Haas, D. M., & Quinney, S. K. (2023). Pharmacokinetics of Antidepressants in Pregnancy. Jour-nal Of Clinical Pharmacology, 63 Suppl 1(Suppl 1), S137-S158. https://doi.org/10.1002/jcph.2282 google scholar
74. Zerfas, I., McGinn, R., Smith, M. A. (2023). Pharmacologic Manage-ment of Cancer-Related Pain in Pregnant Patients. Drugs, 83(12), 1067-1076. https://doi.org/10.1007/s40265-023-01906-4 google scholar
75. Zoega, H., Kieler, H., N0rgaard, M., Furu, K., Valdimarsdottir, U., Brandt, L., & Haglund, B. (2015). Use of SSRI and SNRI Antide-pressants during Pregnancy: A Population-Based Study from Den-mark, Iceland, Norway and Sweden. Plos One, 10(12), e0144474. https://doi.org/10.1371/journal.pone.0144474 google scholar